Vertex Pharmaceuticals (VRTX) Non Operating Income (2012 - 2018)
Vertex Pharmaceuticals (VRTX) posted quarterly Non Operating Income of -$4.8 million for Q4 2018, up 61.96% year-over-year from -$2.9 million in Q4 2017, and up 41.39% quarter-over-quarter from -$8.1 million in Q3 2018.
Vertex Pharmaceuticals (VRTX) Non Operating Income (2012 - 2018) Analysis & Trends
Vertex Pharmaceuticals' Non Operating Income history runs 7 years deep, the most recent figure standing at -$4.8 million for Q4 2018.
- In Q4 2018, Non Operating Income rose 61.96% year-over-year to -$4.8 million; the TTM figure through Dec 2018 stood at -$34.1 million (up 40.71% YoY), while the FY2018 annual figure was -$34.1 million, up 40.71% from the prior year.
- Non Operating Income for Q4 2018 stood at -$4.8 million, up from -$8.1 million in the prior quarter.
- The five-year high for Non Operating Income was -$4.8 million in Q4 2018, with the low at -$21.3 million in Q1 2015.
- The 5-year median for Non Operating Income is -$18.5 million (2016), against an average of -$16.5 million.
- The sharpest annual moves came in 2014 and 2018: Non Operating Income sank 19500.0% in 2014, then jumped 61.96% in 2018.
- Vertex Pharmaceuticals' Non Operating Income stood at -$21.2 million in 2014, then grew by 2.47% to -$20.7 million in 2015, then rose by 1.04% to -$20.4 million in 2016, then soared by 38.61% to -$12.5 million in 2017, then surged by 61.96% to -$4.8 million in 2018.
- Business Quant data shows VRTX's Non Operating Income at -$4.8 million in Q4 2018, -$8.1 million in Q3 2018, and -$10.1 million in Q2 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | -4.77 Mn |
| Sep 30, 2018 | -8.14 Mn |
| Jun 30, 2018 | -10.11 Mn |
| Mar 31, 2018 | -11.10 Mn |
| Dec 31, 2017 | -12.55 Mn |
| Sep 30, 2017 | -13.57 Mn |
| Jun 30, 2017 | -14.66 Mn |
| Mar 31, 2017 | -16.77 Mn |
| Dec 31, 2016 | -20.44 Mn |
| Sep 30, 2016 | -20.14 Mn |
| Jun 30, 2016 | -20.16 Mn |
| Mar 31, 2016 | -20.70 Mn |
| Dec 31, 2015 | -20.65 Mn |
| Sep 30, 2015 | -21.13 Mn |
| Jun 30, 2015 | -21.11 Mn |
| Mar 31, 2015 | -21.31 Mn |
| Dec 31, 2014 | -21.18 Mn |
| Sep 30, 2014 | -20.38 Mn |
| Jun 30, 2014 | -15.59 Mn |
| Mar 31, 2014 | -15.72 Mn |